ZA201302537B - Stable and soluble antibodies - Google Patents

Stable and soluble antibodies

Info

Publication number
ZA201302537B
ZA201302537B ZA2013/02537A ZA201302537A ZA201302537B ZA 201302537 B ZA201302537 B ZA 201302537B ZA 2013/02537 A ZA2013/02537 A ZA 2013/02537A ZA 201302537 A ZA201302537 A ZA 201302537A ZA 201302537 B ZA201302537 B ZA 201302537B
Authority
ZA
South Africa
Prior art keywords
stable
soluble antibodies
antibodies
soluble
Prior art date
Application number
ZA2013/02537A
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Original Assignee
Esbatech - A Novartis Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44897558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201302537(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech - A Novartis Company Llc filed Critical Esbatech - A Novartis Company Llc
Publication of ZA201302537B publication Critical patent/ZA201302537B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA2013/02537A 2010-10-22 2013-04-09 Stable and soluble antibodies ZA201302537B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40579810P 2010-10-22 2010-10-22
US201161484749P 2011-05-11 2011-05-11
PCT/CH2011/000256 WO2012051734A1 (en) 2010-10-22 2011-10-24 Stable and soluble antibodies

Publications (1)

Publication Number Publication Date
ZA201302537B true ZA201302537B (en) 2014-06-25

Family

ID=44897558

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/02537A ZA201302537B (en) 2010-10-22 2013-04-09 Stable and soluble antibodies

Country Status (21)

Country Link
US (3) US8545849B2 (en:Method)
EP (2) EP3336105B1 (en:Method)
JP (4) JP6245985B2 (en:Method)
KR (4) KR20160083970A (en:Method)
CN (2) CN103154033B (en:Method)
AR (1) AR083495A1 (en:Method)
AU (1) AU2011318179B2 (en:Method)
BR (1) BR112013010949B1 (en:Method)
CA (1) CA2814766C (en:Method)
CL (2) CL2013001089A1 (en:Method)
CO (1) CO6741152A2 (en:Method)
CY (1) CY1119941T1 (en:Method)
MX (2) MX351499B (en:Method)
PH (1) PH12013500675B1 (en:Method)
PL (1) PL2630159T3 (en:Method)
RU (2) RU2558298C2 (en:Method)
TW (3) TWI652068B (en:Method)
UA (1) UA111340C2 (en:Method)
UY (1) UY33679A (en:Method)
WO (1) WO2012051734A1 (en:Method)
ZA (1) ZA201302537B (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628686B1 (en) * 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2012325232B2 (en) * 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
EP2809344B1 (en) 2012-02-02 2016-08-24 ESBATech - a Novartis Company LLC Antibody-containing sustained-release formulation for ocular administration
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
US20140186350A1 (en) 2012-12-18 2014-07-03 Novartis Ag Compositions and methods for long acting molecules
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
CA2964786C (en) 2014-10-23 2023-10-17 Amgen Inc. Reducing the viscosity of pharmaceutical formulations with n-acetyl amino acids
SG11201803009VA (en) 2015-11-02 2018-05-30 Five Prime Therapeutics Inc Cd80 extracellular domain polypeptides and their use in cancer treatment
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017221128A1 (en) 2016-06-20 2017-12-28 Novartis Ag Methods of treating dry eye disease using tnf alpha antagonists
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
EP3997124A4 (en) * 2019-07-09 2024-01-03 National Institute for Biotechnology in the Negev Ltd. ANTIBODIES WITH REDUCED IMMUNOGENICITY
CN112786101B (zh) * 2019-11-07 2024-11-12 中国农业大学 热稳定性抗体的制备方法
US20230046834A1 (en) * 2019-11-21 2023-02-16 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5213656A (en) 1991-12-04 1993-05-25 Gerber Scientific Products, Inc. Method of using a web for etching of a surface
KR100372119B1 (ko) * 1992-07-13 2003-06-28 유카리언, 인코포레이티드 지질화된단백질을경혈관적및세포내로전달하는방법
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
JP2000516452A (ja) * 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US6470213B1 (en) 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003097697A2 (en) 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2523124A1 (en) 2003-03-20 2004-10-07 Gary D. Niehaus Self-contained assay device for rapid detection of biohazardous agents
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
CA2533830A1 (en) 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20080003617A1 (en) 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
PT2390267E (pt) 2005-06-07 2013-07-16 Esbatech A Novartis Co Llc Anticorpos estáveis e solúveis que inibem tnf(alfa)
CN101948541B (zh) 2005-06-20 2014-08-06 健泰科生物技术公司 用于肿瘤诊断和治疗的组合物和方法
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
CA2625222A1 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007109254A2 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
DK2013236T3 (en) 2006-04-28 2015-09-21 Delenex Therapeutics Ag ANTIBODIES WHICH BIND TO the extracellular domain of the receptor ALK
US8524865B2 (en) 2006-05-30 2013-09-03 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
ES2603399T3 (es) 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
ES2442258T3 (es) 2006-10-27 2014-02-10 Abbvie Biotechnology Ltd Anticuerpos cristalinos anti-hTNF alfa
EP2089059A2 (en) 2006-11-10 2009-08-19 Genentech, Inc. Method for treating age-related macular degeneration
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
TWI501976B (zh) 2007-05-21 2015-10-01 Alder Biopharmaceuticals Inc 抗ＴＮＦ－α之抗體及其用途
DK2158315T3 (en) * 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
WO2009052140A1 (en) * 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
US8399627B2 (en) * 2007-12-31 2013-03-19 Bayer Pharma AG Antibodies to TNFα
RU2567100C2 (ru) * 2008-06-25 2015-10-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
LT3241843T (lt) 2008-06-25 2021-09-27 Novartis Ag Imuninių rišiklių tirpumo optimizavimas
EP3628686B1 (en) 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
SI2307454T1 (sl) 2008-06-25 2017-05-31 ESBA Tech, an Alcon Biomedical Research Unit LLC Stabilna in topna protitelesa, ki inhibirajo VEGF
MX2011000006A (es) 2008-06-30 2011-08-03 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
BRPI0915460A2 (pt) 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
EP2918602A1 (en) 2009-04-16 2015-09-16 AbbVie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
MX352871B (es) 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
CN103096927A (zh) 2010-07-15 2013-05-08 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗胃肠道功能性疾病或病症的方法
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
UY33702A (es) 2010-11-02 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
RU2014120755A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммуносвязующие агенты, направленные против tnf

Also Published As

Publication number Publication date
EP2630159B1 (en) 2017-11-22
AU2011318179A1 (en) 2013-05-02
JP7148228B2 (ja) 2022-10-05
CA2814766A1 (en) 2012-04-26
KR101635917B1 (ko) 2016-07-04
CA2814766C (en) 2017-11-28
RU2013123266A (ru) 2014-11-27
CL2013001089A1 (es) 2014-03-07
US20120100153A1 (en) 2012-04-26
UY33679A (es) 2012-03-30
JP2013544078A (ja) 2013-12-12
BR112013010949B1 (pt) 2022-02-01
CN108359012B (zh) 2021-12-24
EP3336105B1 (en) 2020-11-04
KR20190016137A (ko) 2019-02-15
MX2013004295A (es) 2013-06-05
CL2015002735A1 (es) 2016-03-04
CN103154033B (zh) 2018-04-24
AU2011318179B2 (en) 2014-12-11
KR20130138806A (ko) 2013-12-19
BR112013010949A2 (en:Method) 2017-09-05
PL2630159T3 (pl) 2018-04-30
JP6245985B2 (ja) 2017-12-13
US20130344086A1 (en) 2013-12-26
JP2019054814A (ja) 2019-04-11
PH12013500675A1 (en:Method) 2013-06-10
TWI702230B (zh) 2020-08-21
AR083495A1 (es) 2013-02-27
EP3336105A1 (en) 2018-06-20
WO2012051734A1 (en) 2012-04-26
TW201920270A (zh) 2019-06-01
RU2015119440A (ru) 2015-11-27
TW201221142A (en) 2012-06-01
CO6741152A2 (es) 2013-08-30
PH12013500675B1 (en) 2017-09-06
US8545849B2 (en) 2013-10-01
UA111340C2 (uk) 2016-04-25
US20160176959A1 (en) 2016-06-23
TWI652068B (zh) 2019-03-01
CY1119941T1 (el) 2018-12-12
US9598487B2 (en) 2017-03-21
US10570198B2 (en) 2020-02-25
KR101947520B1 (ko) 2019-02-14
EP2630159A1 (en) 2013-08-28
TWI584816B (zh) 2017-06-01
RU2558298C2 (ru) 2015-07-27
KR20160083970A (ko) 2016-07-12
CN103154033A (zh) 2013-06-12
JP2015193664A (ja) 2015-11-05
CN108359012A (zh) 2018-08-03
KR20170020558A (ko) 2017-02-22
TW201630623A (zh) 2016-09-01
JP2017184770A (ja) 2017-10-12
RU2015119440A3 (en:Method) 2019-01-28
MX351499B (es) 2017-10-17

Similar Documents

Publication Publication Date Title
ZA201302537B (en) Stable and soluble antibodies
RS62700B1 (sr) Anti-cd277 antitela i njihove upotrebe
SI3333188T1 (sl) Protitelesa proti NGF in njihova uporaba
IL222852A0 (en) Anti-fgfr2 antibodies
PT2581113T (pt) Anticorpo anti-tim-3
LT3342786T (lt) Anti-dll3 antikūnai
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
ZA201208541B (en) Antibody preparations
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
GB201020738D0 (en) Antibodies
SG10201501285RA (en) Anti-alpha2 integrin antibodies and their uses
EP2629796A4 (en) ANTIBODY
GB201002238D0 (en) Antibodies
RS56862B1 (sr) Stabilna i rastvorljiva antitela
HUE036125T2 (hu) Stabil és oldható antitestek
GB201007957D0 (en) Antibody
HK1188458A (en) Anti-sod1 antibodies and uses thereof
GB201017780D0 (en) Antibody
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies